← BackALIGN TECHNOLOGY INC · Orthopedic, Prosthetic & Surgical Appliances & SuppliesALGN
Low riskNext report: In 1 days (est.)
The short versionA high-quality, profitable business with steady sales.
Going well
- Profitable every year for 10 years
- Brings in more cash than it spends
- Buying back shares: share count down 7.4% in 3 years
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 5.1% to their holdings in the quarter ending June 2026 (284 bought, 343 sold)
- Held by Ray Dalio (Bridgewater), Cathie Wood (ARK Invest)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$152.31-1.4% that day
- Company value
- $10.8B
- Share price times all shares
- Price vs profit (P/E)
- 26.5x
- You pay about $27 for each $1 of yearly profit
- Price vs sales
- 2.6x
- Company value is 2.6 times a year of sales
- Cash vs value
- 10%
- Cash as a share of company value
From ALGN's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$1.1B+4.3% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $4.1B, up 4.4% from the 12 months before. Over 5 years, sales grew about 10% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.10.4%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.10.2%
- PassProfitable every yearSteady profits, not one good year.10 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$490.8M
- PassShare count not growingNot diluting owners. Falling means buybacks.-7.4% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.67.2%
- Revenue
- $4.0B
- +0.9% vs prior year
- 5-year growth
- +10.3%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 1.36x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $1.1B
- +4.3% YoY
- EPS
- $1.51
- vs $1.72
- Op. margin
- 14.6%
- -1.5 pts
- Gross margin
- 71.7%
- +1.8 pts
- Free cash flow
- $157.1M
- Share count
- -1.5%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.7
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+5.1%Institutions added 5.1% to their holdings. 284 bought, 343 sold. 2 quarters of net buying in a row.
Shares held by institutions73.0M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-2.4%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
71MNext reportIn 1 days (est.)Estimated from the same quarter last year
- Results filedJul 29
- Results filedApr 29
- Results filedFeb 4
- Results filedOct 29, 2025
- Results filedJul 30, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.